Naratuximab provides a CD37-targeting monoclonal antibody for lymphoma, leukemia, and antibody research. It recognizes CD37, a cell-surface tetraspanin protein expressed predominantly on mature B cells and many B-cell malignancies and specifically supports studies of tumor antigen recognition, antibody-mediated cellular targeting, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CD37-Targeting Antibody: Recognizes CD37, a B-cell-associated surface antigen involved in cellular signaling and immune regulation.
- Monoclonal Antibody Platform: Provides an antibody specifically for investigating selective CD37 recognition and malignant B-cell targeting.
- CD37 Recognition: Supports investigation of CD37 expression, antibody binding, internalization, and antigen-specific cellular interactions.
- B-Cell Malignancy Targeting: Enables studies of antibody binding to CD37-expressing lymphoma and leukemia cells.
- ADC Development Platform: Provides the antibody component specifically associated with Naratuximab Emtansine (IMGN529), an investigational CD37-directed ADC containing the maytansinoid DM1 payload.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in CD37-expressing cells.
- Immune Effector Function Research: Supports studies of antibody-mediated immune responses, specifically including antibody-dependent cellular cytotoxicity.
- Antibody Engineering Research: Useful for investigating antibody conjugation, antigen specificity, and targeted payload delivery strategies.
Applications
- Non-Hodgkin Lymphoma Research: Supports investigation of CD37-targeted antibody strategies in non-Hodgkin lymphoma models.
- Diffuse Large B-Cell Lymphoma Research: Especially useful specifically for studying CD37 expression and antibody recognition in DLBCL models.
- Chronic Lymphocytic Leukemia Research: Supports evaluation of CD37-directed targeting strategies in relevant CLL models.
- CD37-Positive Cancer Research: Enables investigation of antigen expression and antibody interactions in CD37-expressing malignant cells.
- B-Cell Biology Research: Supports studies of CD37 expression, tetraspanin-associated signaling, and B-cell cellular functions.
- ADC Research: Provides a targeting antibody platform for investigating CD37-directed payload conjugation and delivery.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in CD37-expressing cells.
- Comparative Antibody Research: Useful for comparing CD37-targeting antibodies, immune effector mechanisms, and antibody-mediated B-cell recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Naratuximab provides a CD37-directed monoclonal antibody for investigating B-cell antigen recognition and targeted cancer cell binding and specifically supports non-Hodgkin lymphoma, chronic lymphocytic leukemia, B-cell biology, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
